These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 19895921)

  • 1. Viraemia and clinical disease in Dorset Poll sheep following vaccination with live attenuated bluetongue virus vaccines serotypes 16 and 4.
    Veronesi E; Darpel KE; Hamblin C; Carpenter S; Takamatsu HH; Anthony SJ; Elliott H; Mertens PP; Mellor PS
    Vaccine; 2010 Feb; 28(5):1397-403. PubMed ID: 19895921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccines against bluetongue in Europe.
    Savini G; MacLachlan NJ; Sanchez-Vizcaino JM; Zientara S
    Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):101-20. PubMed ID: 17765305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine.
    Moulin V; Noordegraaf CV; Makoschey B; van der Sluijs M; Veronesi E; Darpel K; Mertens PP; de Smit H
    Vaccine; 2012 Mar; 30(12):2228-35. PubMed ID: 22207091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Live attenuated bluetongue vaccine viruses in Dorset Poll sheep, before and after passage in vector midges (Diptera: Ceratopogonidae).
    Veronesi E; Hamblin C; Mellor PS
    Vaccine; 2005 Dec; 23(48-49):5509-16. PubMed ID: 16111787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of the minimum protective dose for bluetongue virus serotype 2 and 8 vaccines in sheep.
    Modumo J; Venter EH
    J S Afr Vet Assoc; 2012 Aug; 83(1):17. PubMed ID: 23327131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bluetongue virus without NS3/NS3a expression is not virulent and protects against virulent bluetongue virus challenge.
    Feenstra F; van Gennip RGP; Maris-Veldhuis M; Verheij E; van Rijn PA
    J Gen Virol; 2014 Sep; 95(Pt 9):2019-2029. PubMed ID: 24914064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of potential bluetongue virus vaccine strategies.
    Mayo C; Lee J; Kopanke J; MacLachlan NJ
    Vet Microbiol; 2017 Jul; 206():84-90. PubMed ID: 28377132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of vaccination for bluetongue virus serotype 8 performed shortly before challenge and implications for animal trade.
    Spedicato M; Lorusso A; Salini R; Gennaro AD; Leone A; Teodori L; Casaccia C; Portanti O; Calistri P; Giovannini A; Savini G
    Prev Vet Med; 2017 Jan; 136():49-55. PubMed ID: 28010907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective duration of immunity of an inactivated bluetongue (BTV) serotype 2 vaccine against a virulent BTV serotype 2 challenge in sheep.
    Hamers C; Rehbein S; Hudelet P; Blanchet M; Lapostolle B; Cariou C; Duboeuf M; Goutebroze S
    Vaccine; 2009 May; 27(21):2789-93. PubMed ID: 19366576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the humoral response between sheep vaccinated with a killed-virus vaccine and those vaccinated with a modified-live virus vaccine against bluetongue virus serotype 17.
    Speiser KL; Schumaker BA; Cook WE; Cornish TE; Cammack KM; Miller MM
    J Am Vet Med Assoc; 2016 May; 248(9):1043-9. PubMed ID: 27074613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duration of viraemia infectious to Culicoides sonorensis in bluetongue virus-infected cattle and sheep.
    Bonneau KR; DeMaula CD; Mullens BA; MacLachlan NJ
    Vet Microbiol; 2002 Aug; 88(2):115-25. PubMed ID: 12135632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence of reduced viremia, pathogenicity and vector competence in a re-emerging European strain of bluetongue virus serotype 8 in sheep.
    Flannery J; Sanz-Bernardo B; Ashby M; Brown H; Carpenter S; Cooke L; Corla A; Frost L; Gubbins S; Hicks H; Qureshi M; Rajko-Nenow P; Sanders C; Tully M; Bréard E; Sailleau C; Zientara S; Darpel K; Batten C
    Transbound Emerg Dis; 2019 May; 66(3):1177-1185. PubMed ID: 30661301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-propiolactone inactivated bivalent bluetongue virus vaccine containing Montanide ISA-71VG adjuvant induces long-term immune response in sheep against serotypes 4 and 16 even after 3 years of controlled vaccine storage.
    Zhugunissov K; Bulatov Y; Taranov D; Yershebulov Z; Koshemetov Z; Zhunushov A; Renukaradhya GJ; Tabynov K; Abduraimov Y
    Vet Microbiol; 2018 Nov; 226():23-30. PubMed ID: 30389040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An inactivated vaccine for the control of bluetongue virus serotype 16 infection in sheep in Italy.
    Savini G; Ronchi GF; Leone A; Ciarelli A; Migliaccio P; Franchi P; Mercante MT; Pini A
    Vet Microbiol; 2007 Sep; 124(1-2):140-6. PubMed ID: 17499459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines.
    Breard E; Belbis G; Viarouge C; Nomikou K; Haegeman A; De Clercq K; Hudelet P; Hamers C; Moreau F; Lilin T; Durand B; Mertens P; Vitour D; Sailleau C; Zientara S
    Vaccine; 2015 Jan; 33(4):512-8. PubMed ID: 25500308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transplacental transmission of BTV-8 in sheep: BTV viraemia, antibody responses and vaccine efficacy in lambs infected in utero.
    van der Sluijs MT; Schroer-Joosten DP; Fid-Fourkour A; Smit M; Vrijenhoek MP; Moulin V; de Smit AJ; Moormann RJ
    Vaccine; 2013 Aug; 31(36):3726-31. PubMed ID: 23746457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bluetongue viruses based on modified-live vaccine serotype 6 with exchanged outer shell proteins confer full protection in sheep against virulent BTV8.
    van Gennip RG; van de Water SG; Maris-Veldhuis M; van Rijn PA
    PLoS One; 2012; 7(9):e44619. PubMed ID: 23049753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The spread of bluetongue virus serotype 8 in Great Britain and its control by vaccination.
    Szmaragd C; Wilson AJ; Carpenter S; Wood JL; Mellor PS; Gubbins S
    PLoS One; 2010 Feb; 5(2):e9353. PubMed ID: 20179768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors associated with the occurrence of undesired effects in sheep and goats after field vaccination with modified-live vaccine against bluetongue virus serotypes 2, 4 and 16.
    Savini G; Cannas A; Casaccia C; Di Gialleonardo L; Leone A; Patta C; Nicolussi P
    Vet Microbiol; 2010 Nov; 146(1-2):44-50. PubMed ID: 20537822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective efficacy of Bluetongue virus-like and subvirus-like particles in sheep: presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection.
    Stewart M; Dovas CI; Chatzinasiou E; Athmaram TN; Papanastassopoulou M; Papadopoulos O; Roy P
    Vaccine; 2012 Mar; 30(12):2131-9. PubMed ID: 22285887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.